lomustine has been researched along with Canine Diseases in 55 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate if triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro." | 8.31 | Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro. ( Fuchs, D; Morandi, L; Nytko, KJ; Rohrer Bley, C; Tonon, C; Weyland, MS, 2023) |
| "Lomustine, vincristine, procarbazine and prednisolone (LOPP) chemotherapy has been suggested to be an effective treatment for dogs with naïve non-indolent T-cell lymphoma (TCL)." | 8.12 | Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy. ( Blaxill, J; Buzzacott, P; Finlay, J, 2022) |
| " The objective of the present study was to investigate if a shorter protocol combined with an oral lomustine maintenance treatment (3 × in 8 weeks) would present an acceptable result, both for B- and T-cell lymphomas, and for the different types of lymphomas normally encountered in private veterinary practice." | 8.12 | Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma. ( Eberle, N; Limmer, S; Nerschbach, V; Simon Betz, D; Teske, E, 2022) |
| "Multi-agent chemotherapy (vincristine, epirubicin and prednisolone) including either cyclophosphamide (CEOP) or lomustine (LEOP) was given as first-line chemotherapy to treatment-naïve canine lymphoma patients with measurable, high grade T-cell lymphoma (HGTCL)." | 7.91 | A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017). ( Baines, S; Elliott, J, 2019) |
| "The aims of this study were to report treatment outcomes for dogs with histiocytic sarcoma (HS) treated with both lomustine and epirubicin, and to report response rates to epirubicin as a rescue therapy in dogs previously treated with lomustine." | 7.88 | Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy. ( Blackwood, L; Finotello, R; Mason, SL, 2018) |
| "To describe a chemotherapy protocol combining lomustine and doxorubicin in canine histiocytic sarcoma, including outcomes and toxicity." | 7.81 | Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma. ( Borgatti, A; Cannon, C; Henson, M; Husbands, B, 2015) |
| "To compare oral administration of lomustine and prednisolone with oral administration of prednisolone alone as treatment for granulomatous meningoencephalomyelitis (GME) or necrotizing encephalitis (NE) in dogs." | 7.77 | Comparison of oral administration of lomustine and prednisolone or prednisolone alone as treatment for granulomatous meningoencephalomyelitis or necrotizing encephalitis in dogs. ( Boettcher, IC; Doherr, MG; Flegel, T; Henke, D; Matiasek, K; Oechtering, G; Oevermann, A, 2011) |
| "The University of Florida LOPP protocol may be an acceptable alternative to the mechlorethamine, vincristine, procarbazine, and prednisone protocol as a rescue protocol for dogs with lymphoma." | 7.77 | Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003-2009). ( Barabas, K; Clemente, M; Fahey, CE; Kow, K; Lurie, D; Lyles, S; Milner, RJ; Parfitt, S, 2011) |
| "To assess response rate, median duration of response, adverse effects, and prognostic factors associated with concurrent administration of lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma." | 7.74 | Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005). ( Bannink, EO; Kaneene, JB; Mullins, MN; Obradovich, JE; Sauerbrey, ML; Van Dorp, TE, 2007) |
| "Intracranial gliomas are a common malignancy in dogs, and are associated with a poor prognosis due to their aggressive nature and a lack of clinically effective treatments." | 5.48 | Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017). ( Cohen, PW; Dewey, CW; Moirano, SJ; Wright, KZ, 2018) |
| "Lomustine is a well-accepted, first-line chemotherapy for dogs with HS, but its specific utility in dogs with HPHS has not been previously reported." | 5.48 | Lomustine chemotherapy for the treatment of presumptive haemophagocytic histiocytic sarcoma in Flat-coated Retrievers. ( Elliott, J, 2018) |
| "To investigate if triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro." | 4.31 | Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro. ( Fuchs, D; Morandi, L; Nytko, KJ; Rohrer Bley, C; Tonon, C; Weyland, MS, 2023) |
| "Lomustine, vincristine, procarbazine and prednisolone (LOPP) chemotherapy has been suggested to be an effective treatment for dogs with naïve non-indolent T-cell lymphoma (TCL)." | 4.12 | Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy. ( Blaxill, J; Buzzacott, P; Finlay, J, 2022) |
| " The objective of the present study was to investigate if a shorter protocol combined with an oral lomustine maintenance treatment (3 × in 8 weeks) would present an acceptable result, both for B- and T-cell lymphomas, and for the different types of lymphomas normally encountered in private veterinary practice." | 4.12 | Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma. ( Eberle, N; Limmer, S; Nerschbach, V; Simon Betz, D; Teske, E, 2022) |
| "Multi-agent chemotherapy (vincristine, epirubicin and prednisolone) including either cyclophosphamide (CEOP) or lomustine (LEOP) was given as first-line chemotherapy to treatment-naïve canine lymphoma patients with measurable, high grade T-cell lymphoma (HGTCL)." | 3.91 | A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017). ( Baines, S; Elliott, J, 2019) |
| "The aim of this study was to describe the use of a lomustine (CCNU), vincristine, procarbazine and prednisolone (LOPP) protocol used for treatment of chemotherapy naive T-cell lymphoma patients and to describe the response rate, toxicity and disease-free interval compared historically to CHOP chemotherapy." | 3.88 | LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma. ( Brown, PM; Langova, V; Nguyen, S; Tzannes, S; White, J, 2018) |
| "The aims of this study were to report treatment outcomes for dogs with histiocytic sarcoma (HS) treated with both lomustine and epirubicin, and to report response rates to epirubicin as a rescue therapy in dogs previously treated with lomustine." | 3.88 | Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy. ( Blackwood, L; Finotello, R; Mason, SL, 2018) |
| "To describe a chemotherapy protocol combining lomustine and doxorubicin in canine histiocytic sarcoma, including outcomes and toxicity." | 3.81 | Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma. ( Borgatti, A; Cannon, C; Henson, M; Husbands, B, 2015) |
| "To compare oral administration of lomustine and prednisolone with oral administration of prednisolone alone as treatment for granulomatous meningoencephalomyelitis (GME) or necrotizing encephalitis (NE) in dogs." | 3.77 | Comparison of oral administration of lomustine and prednisolone or prednisolone alone as treatment for granulomatous meningoencephalomyelitis or necrotizing encephalitis in dogs. ( Boettcher, IC; Doherr, MG; Flegel, T; Henke, D; Matiasek, K; Oechtering, G; Oevermann, A, 2011) |
| "The University of Florida LOPP protocol may be an acceptable alternative to the mechlorethamine, vincristine, procarbazine, and prednisone protocol as a rescue protocol for dogs with lymphoma." | 3.77 | Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003-2009). ( Barabas, K; Clemente, M; Fahey, CE; Kow, K; Lurie, D; Lyles, S; Milner, RJ; Parfitt, S, 2011) |
| "To assess response rate, median duration of response, adverse effects, and prognostic factors associated with concurrent administration of lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma." | 3.74 | Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005). ( Bannink, EO; Kaneene, JB; Mullins, MN; Obradovich, JE; Sauerbrey, ML; Van Dorp, TE, 2007) |
| "While maintaining a standard toceranib dosage [2." | 2.82 | Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study. ( Kurzman, ID; Pan, X; Tsimbas, K; Vail, DM, 2016) |
| "Several anticancer drugs have been added to the therapeutic armamentarium in recent years." | 2.42 | New chemotherapy agents in veterinary medicine. ( Kitchell, BE; Moore, AS, 2003) |
| "Prednisone was continued at the same dose." | 1.91 | Metastatic Cutaneous Langerhans Cell Histiocytosis in a Flat-Coated Retriever Treated with Doxorubicin and Prednisone. ( Aubry, O; Montesanto, C; Phillips, B, 2023) |
| "Primary pulmonary histiocytic sarcoma (PHS) is a rare form of dendritic cell or macrophage neoplasia originating within the pulmonary parenchyma." | 1.72 | Outcome in dogs with curative-intent treatment of localized primary pulmonary histiocytic sarcoma. ( Al-Nadaf, S; Clifford, C; Cook, MR; De Mello Souza, CH; Herrera, CL; Husbands, B; Krick, E; Leeper, H; McMillan, S; Murray, CA; Pellin, M; Richardson, D; Skorupski, KA; Willcox, JL, 2022) |
| "Lomustine was administered every 3 weeks with three or four planned cycles." | 1.62 | Outcome of dogs with intermediate grade low mitotic index high Ki67 mast cell tumours treated with surgery and single agent lomustine. ( Mason, SL; Néčová, S; North, SM, 2021) |
| "Neutropenia was documented in 20 dogs (57%): 12 grade I to II, 8 grade III to IV." | 1.48 | Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas. ( Amores-Fuster, I; Blackwood, L; Finotello, R; Harper, A; Killick, DR; Maddox, TW; Mason, SL; Tanis, JB, 2018) |
| "Intracranial gliomas are a common malignancy in dogs, and are associated with a poor prognosis due to their aggressive nature and a lack of clinically effective treatments." | 1.48 | Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017). ( Cohen, PW; Dewey, CW; Moirano, SJ; Wright, KZ, 2018) |
| "Lomustine is a well-accepted, first-line chemotherapy for dogs with HS, but its specific utility in dogs with HPHS has not been previously reported." | 1.48 | Lomustine chemotherapy for the treatment of presumptive haemophagocytic histiocytic sarcoma in Flat-coated Retrievers. ( Elliott, J, 2018) |
| "Lomustine was administered, but 1 year after surgery, the dog exhibited cluster seizures and died." | 1.43 | Case of a miniature dachshund with a primitive neuroectodermal tumor confined to the forebrain region treated with a combination of surgery and chemotherapy. ( Matsunaga, S; Nakamoto, Y; Ozawa, T; Uchida, K; Yamada, A, 2016) |
| "To describe a case of canine multiple cutaneous histiocytomas treated with lomustine." | 1.40 | Multiple cutaneous histiocytomas treated with lomustine in a dog. ( Colombo, S; Maina, E; Stefanello, D, 2014) |
| "Multifocal histiocytic sarcoma with a spindle-cell pattern was diagnosed based on morphologic features and intense expression of CD18." | 1.38 | Multifocal cutaneous histiocytic sarcoma in a young dog and review of histiocytic cell immunophenotyping. ( Aubry, OA; Christopherson, PW; Kennis, RA; Mastrorilli, C; Moore, PF; Newton, JC; Smith, AN; Spangler, EA; Weismann, JL, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.82) | 18.2507 |
| 2000's | 11 (20.00) | 29.6817 |
| 2010's | 32 (58.18) | 24.3611 |
| 2020's | 11 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blaxill, J | 1 |
| Buzzacott, P | 1 |
| Finlay, J | 1 |
| Murray, CA | 1 |
| Willcox, JL | 1 |
| De Mello Souza, CH | 1 |
| Husbands, B | 2 |
| Cook, MR | 1 |
| Clifford, C | 1 |
| Leeper, H | 1 |
| Pellin, M | 1 |
| Richardson, D | 1 |
| Herrera, CL | 1 |
| Krick, E | 1 |
| McMillan, S | 1 |
| Al-Nadaf, S | 1 |
| Skorupski, KA | 2 |
| Patten, S | 1 |
| MacKenzie, S | 1 |
| Limmer, S | 2 |
| Nerschbach, V | 2 |
| Eberle, N | 2 |
| Teske, E | 2 |
| Simon Betz, D | 2 |
| Fuchs, D | 1 |
| Rohrer Bley, C | 1 |
| Morandi, L | 1 |
| Tonon, C | 1 |
| Weyland, MS | 1 |
| Nytko, KJ | 1 |
| Montesanto, C | 1 |
| Phillips, B | 1 |
| Aubry, O | 1 |
| Soileau, AM | 1 |
| Neto, RLALT | 1 |
| Jimenez, PT | 1 |
| Hamersky, J | 1 |
| Smith, AA | 1 |
| Purzycka, K | 2 |
| Peters, LM | 2 |
| Desmas, I | 1 |
| Davies, O | 1 |
| Chang, YM | 1 |
| Lara-Garcia, A | 2 |
| Elliott, J | 3 |
| Lamb, CR | 1 |
| Priestnall, SL | 1 |
| Hardas, A | 1 |
| Johnston, CA | 1 |
| Rodriguez-Piza, I | 1 |
| Dedeaux, AM | 1 |
| Flesner, BK | 1 |
| Reinhart, JM | 1 |
| Langohr, IM | 1 |
| Husnik, R | 1 |
| Geraci, SN | 1 |
| Taboada, J | 1 |
| Rademacher, N | 1 |
| Thombs, LA | 1 |
| Bryan, JN | 1 |
| Trepanier, LA | 1 |
| Boudreaux, BB | 1 |
| Néčová, S | 1 |
| Mason, SL | 3 |
| North, SM | 1 |
| Brown, PM | 1 |
| Tzannes, S | 1 |
| Nguyen, S | 1 |
| White, J | 1 |
| Langova, V | 1 |
| Boostrom, BO | 1 |
| Moore, AS | 2 |
| DeRegis, CJ | 1 |
| Robat, C | 1 |
| Freeman, K | 1 |
| Thamm, DH | 1 |
| Finotello, R | 2 |
| Blackwood, L | 2 |
| Bavcar, S | 1 |
| de Vos, J | 2 |
| Kessler, M | 1 |
| de Fornel, P | 1 |
| Buracco, P | 1 |
| Murphy, S | 1 |
| Hirschberger, J | 1 |
| Argyle, DJ | 1 |
| Tanis, JB | 1 |
| Maddox, TW | 1 |
| Killick, DR | 1 |
| Amores-Fuster, I | 1 |
| Harper, A | 1 |
| Duffy, ME | 1 |
| Anderson, CL | 1 |
| Choy, K | 1 |
| Fidel, JL | 1 |
| Moirano, SJ | 1 |
| Dewey, CW | 1 |
| Wright, KZ | 1 |
| Cohen, PW | 1 |
| Morgan, E | 1 |
| O'Connell, K | 1 |
| Thomson, M | 1 |
| Griffin, A | 1 |
| Baines, S | 1 |
| Lejeune, A | 1 |
| Skorupski, K | 1 |
| Frazier, S | 1 |
| Vanhaezebrouck, I | 1 |
| Rebhun, RB | 1 |
| Reilly, CM | 1 |
| Rodriguez, CO | 2 |
| Ueno, H | 1 |
| Miyoshi, K | 1 |
| Fukui, S | 1 |
| Kondo, Y | 1 |
| Matsuda, K | 1 |
| Uchide, T | 2 |
| Pan, X | 1 |
| Tsimbas, K | 1 |
| Kurzman, ID | 1 |
| Vail, DM | 1 |
| Maina, E | 1 |
| Colombo, S | 1 |
| Stefanello, D | 1 |
| Cannon, C | 1 |
| Borgatti, A | 1 |
| Henson, M | 1 |
| Yamazaki, H | 1 |
| Takagi, S | 1 |
| Hosoya, K | 2 |
| Okumura, M | 1 |
| Kambayashi, S | 1 |
| Minami, K | 1 |
| Ogawa, Y | 1 |
| Hamaji, T | 1 |
| Hwang, CC | 1 |
| Igase, M | 1 |
| Hiraoka, H | 1 |
| Miyama, TS | 1 |
| Noguchi, S | 1 |
| Baba, K | 1 |
| Mizuno, T | 1 |
| Okuda, M | 1 |
| Nakamoto, Y | 1 |
| Yamada, A | 1 |
| Uchida, K | 2 |
| Matsunaga, S | 1 |
| Ozawa, T | 1 |
| Laprais, A | 1 |
| Olivry, T | 1 |
| Vincenti, S | 1 |
| Findji, F | 1 |
| Fontaine, J | 1 |
| Bovens, C | 1 |
| Bettenay, S | 1 |
| Mueller, RS | 1 |
| Intile, JL | 3 |
| Rassnick, KM | 4 |
| Bailey, DB | 3 |
| Al-Sarraf, R | 2 |
| Chretin, JD | 1 |
| Balkman, CE | 3 |
| Flory, AB | 3 |
| Kiselow, MA | 3 |
| Wakshlag, JJ | 2 |
| Krick, EL | 1 |
| Clifford, CA | 1 |
| Ward, R | 1 |
| Kent, MS | 1 |
| Cooper, M | 1 |
| Tsai, X | 1 |
| Bennett, P | 1 |
| Lord, LK | 1 |
| Kisseberth, WC | 1 |
| London, CA | 1 |
| Couto, CG | 1 |
| Russell, DS | 2 |
| Malone, EK | 3 |
| Barnard, SM | 2 |
| Ruslander, DM | 1 |
| Johnson, CS | 1 |
| Trump, DL | 1 |
| Barlow, LL | 1 |
| Waite, AH | 1 |
| Flegel, T | 1 |
| Boettcher, IC | 1 |
| Matiasek, K | 1 |
| Oevermann, A | 1 |
| Doherr, MG | 1 |
| Oechtering, G | 1 |
| Henke, D | 1 |
| Heading, KL | 1 |
| Brockley, LK | 1 |
| Bennett, PF | 1 |
| Abrams-Ogg, AC | 1 |
| Fahey, CE | 1 |
| Milner, RJ | 1 |
| Barabas, K | 1 |
| Lurie, D | 1 |
| Kow, K | 1 |
| Parfitt, S | 1 |
| Lyles, S | 1 |
| Clemente, M | 1 |
| Fukumoto, S | 1 |
| Hanazono, K | 1 |
| Kawasaki, N | 1 |
| Hori, Y | 1 |
| Higuchi, S | 1 |
| Sasaki, T | 1 |
| Temma, K | 1 |
| Van Meervenne, S | 1 |
| Verhoeven, PS | 1 |
| Gielen, IM | 1 |
| Polis, I | 1 |
| Van Ham, LM | 1 |
| Mastrorilli, C | 1 |
| Spangler, EA | 1 |
| Christopherson, PW | 1 |
| Aubry, OA | 1 |
| Newton, JC | 1 |
| Smith, AN | 1 |
| Kennis, RA | 1 |
| Weismann, JL | 1 |
| Moore, PF | 1 |
| Hasegawa, D | 1 |
| Kuwabara, T | 1 |
| Mizoguchi, S | 1 |
| Yayoshi, N | 1 |
| Fujita, M | 1 |
| Szabo, D | 1 |
| Saveraid, TC | 1 |
| Rodenas, S | 1 |
| Kitchell, BE | 1 |
| Jung, DI | 2 |
| Kim, HJ | 2 |
| Park, C | 2 |
| Kim, JW | 2 |
| Kang, BT | 2 |
| Lim, CY | 2 |
| Park, EH | 1 |
| Sur, JH | 1 |
| Seo, MH | 1 |
| Hahm, DH | 1 |
| Park, HM | 2 |
| Baldi, A | 1 |
| Colloca, E | 1 |
| Spugnini, EP | 1 |
| Jeong, SW | 1 |
| Rusk, A | 1 |
| Cozzi, E | 1 |
| Stebbins, M | 1 |
| Vail, D | 1 |
| Graham, J | 1 |
| Valli, V | 1 |
| Henkin, J | 1 |
| Sharpee, R | 1 |
| Khanna, C | 1 |
| Sauerbrey, ML | 1 |
| Mullins, MN | 1 |
| Bannink, EO | 1 |
| Van Dorp, TE | 1 |
| Kaneene, JB | 1 |
| Obradovich, JE | 1 |
| Fulton, LM | 1 |
| Steinberg, HS | 1 |
4 reviews available for lomustine and Canine Diseases
| Article | Year |
|---|---|
Is CCNU (lomustine) valuable for treatment of cutaneous epitheliotropic lymphoma in dogs? A critically appraised topic.
Topics: Animals; Antineoplastic Agents, Alkylating; Dog Diseases; Dogs; Lomustine; Lymphoma, T-Cell, Cutaneo | 2017 |
Canine cutaneous epitheliotropic T-cell lymphoma: a review.
Topics: Animals; Antineoplastic Agents, Alkylating; Dog Diseases; Dogs; Epidermis; Female; Humans; Lomustine | 2009 |
New chemotherapy agents in veterinary medicine.
Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Deoxycytidine; Dog Diseases; Dogs; Gemcitabine; | 2003 |
Preliminary study of lomustine in the treatment of intracranial masses in dogs following localization by imaging techniques.
Topics: Animals; Brain Neoplasms; Dog Diseases; Dogs; Lomustine; Magnetic Resonance Imaging; Tomography, X-R | 1990 |
7 trials available for lomustine and Canine Diseases
| Article | Year |
|---|---|
Biochemical, functional, and histopathologic characterization of lomustine-induced liver injury in dogs.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Chemical and Drug Induced Liver Injury, Chronic | 2020 |
Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Combinati | 2016 |
Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Female; Lomustine; Male | 2009 |
A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, | 2010 |
Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Calcitriol; Calcium Channel Agonists; | 2010 |
Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparagine; Cyclophosphamide; Dog Diseases; | 2010 |
Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Disease Progressio | 2006 |
44 other studies available for lomustine and Canine Diseases
| Article | Year |
|---|---|
Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Hypercalcemia; Lomustin | 2022 |
Outcome in dogs with curative-intent treatment of localized primary pulmonary histiocytic sarcoma.
Topics: Animals; Dog Diseases; Dogs; Histiocytic Sarcoma; Lomustine; Lung; Lung Neoplasms; Retrospective Stu | 2022 |
Prolonged Survival Following Treatment of Histiocytic Sarcoma of the Canine Urinary Bladder.
Topics: Animals; Dog Diseases; Dogs; Doxorubicin; Histiocytic Sarcoma; Lomustine; Male; Urinary Bladder | 2022 |
Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Lomustine; Lymphoma; Ly | 2022 |
Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Lomustine; Lymphoma; Ly | 2022 |
Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Lomustine; Lymphoma; Ly | 2022 |
Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Lomustine; Lymphoma; Ly | 2022 |
Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro.
Topics: Animals; Cell Survival; Dacarbazine; Dog Diseases; Dogs; Glioma; Lomustine; Temozolomide | 2023 |
Metastatic Cutaneous Langerhans Cell Histiocytosis in a Flat-Coated Retriever Treated with Doxorubicin and Prednisone.
Topics: Animals; Dog Diseases; Dogs; Doxorubicin; Female; Lomustine; Prednisone; Vinorelbine | 2023 |
Doxorubicin and zoledronate treatment in a dog with hemophagocytic histiocytic sarcoma.
Topics: Animals; Dog Diseases; Dogs; Doxorubicin; Histiocytic Sarcoma; Hyperbilirubinemia; Hypoalbuminemia; | 2023 |
Clinicopathological characteristics and prognostic factors for canine multicentric non-indolent T-cell lymphoma: 107 cases.
Topics: Animals; Antineoplastic Agents, Alkylating; Disease Progression; Dog Diseases; Dogs; Lomustine; Lymp | 2020 |
Histiocytic sarcoma in miniature schnauzers: 30 cases.
Topics: Animals; Dog Diseases; Dogs; Histiocytic Sarcoma; Lomustine; Retrospective Studies | 2020 |
Outcome of dogs with intermediate grade low mitotic index high Ki67 mast cell tumours treated with surgery and single agent lomustine.
Topics: Animals; Dog Diseases; Dogs; Ki-67 Antigen; Lomustine; Mast Cells; Mitotic Index; Retrospective Stud | 2021 |
LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Female; Lomustine; Lymp | 2018 |
Canine Cutaneous Plasmacytosis: 21 Cases (2005-2015).
Topics: Animals; Antineoplastic Agents, Alkylating; Dog Diseases; Dogs; Drug Therapy, Combination; Female; L | 2017 |
Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy.
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Epirubicin; Female; Histiocytic Sarcoma; Lomusti | 2018 |
Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dog Dise | 2017 |
Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Female; Lomustine; Lymp | 2018 |
Metronomic administration of lomustine following palliative radiation therapy for appendicular osteosarcoma in dogs.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Dog Diseases; Dogs; Extremities; Female; Lomustine; | 2018 |
Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017).
Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dog Diseases; Dog | 2018 |
Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dog Diseases; Dogs; | 2018 |
Lomustine chemotherapy for the treatment of presumptive haemophagocytic histiocytic sarcoma in Flat-coated Retrievers.
Topics: Animals; Antineoplastic Agents, Alkylating; Dog Diseases; Dogs; Histiocytic Sarcoma; Lomustine; Lymp | 2018 |
A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017).
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Horm | 2019 |
Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012).
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, | 2015 |
Extranodal lymphoma with peripheral nervous system involvement in a dog.
Topics: Animals; Brachial Plexus; Dog Diseases; Dogs; Fatal Outcome; Female; Lomustine; Lymphoma, Extranodal | 2014 |
Multiple cutaneous histiocytomas treated with lomustine in a dog.
Topics: Animals; Antineoplastic Agents, Alkylating; Dog Diseases; Dogs; Histiocytoma, Benign Fibrous; Lomust | 2014 |
Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; | 2015 |
Influence of a survivin suppressor YM155 on the chemoresistance of canine histiocytic sarcoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dog Diseases; Dogs; Drug Resistance, N | 2015 |
Expression of O(6)-methylguanine-DNA methyltransferase causes lomustine resistance in canine lymphoma cells.
Topics: Animals; Antineoplastic Agents; CpG Islands; DNA Modification Methylases; Dog Diseases; Dogs; Drug R | 2015 |
Case of a miniature dachshund with a primitive neuroectodermal tumor confined to the forebrain region treated with a combination of surgery and chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dog Diseases | 2016 |
Influence of treatment on the outcome of dogs with incompletely excised grade-2 mast cell tumors.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dog Diseases; Dogs; Follow-Up Studies; Lo | 2017 |
Evaluation of dexamethasone as a chemoprotectant for CCNU-induced bone marrow suppression in dogs.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow; Dexamethasone; Dog Diseases; Dogs; Dose-Res | 2009 |
Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy.
Topics: Animals; Antineoplastic Agents; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Dog D | 2009 |
Prevalence of elevated alanine transaminase activity in dogs treated with CCNU (Lomustine)*.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Dog Di | 2009 |
Comparison of oral administration of lomustine and prednisolone or prednisolone alone as treatment for granulomatous meningoencephalomyelitis or necrotizing encephalitis in dogs.
Topics: Administration, Oral; Animals; Dog Diseases; Dogs; Drug Therapy, Combination; Encephalitis; Encephal | 2011 |
CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).
Topics: Anemia; Animals; Antineoplastic Agents, Alkylating; Dog Diseases; Dogs; Female; Gastrointestinal Dis | 2011 |
The use of lithium carbonate to prevent lomustine-induced myelosuppression in dogs: a pilot study.
Topics: Animals; Antidepressive Agents; Antineoplastic Agents, Alkylating; Dog Diseases; Dogs; Dose-Response | 2011 |
Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003-2009).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Drug Resistance, Neopla | 2011 |
Anaplastic atypical myeloma with extensive cutaneous involvement in a dog.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Fatal Outcome; Lomustin | 2012 |
Comparison between symptomatic treatment and lomustine supplementation in 71 dogs with intracranial, space-occupying lesions.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dog Diseases; Dogs; Female; Lomustine; | 2014 |
Multifocal cutaneous histiocytic sarcoma in a young dog and review of histiocytic cell immunophenotyping.
Topics: Animals; Anti-Bacterial Agents; Antigens, CD; Antineoplastic Agents; Biopsy, Fine-Needle; Cephalexin | 2012 |
Long-term survival in a dog with anaplastic oligodendroglioma treated with radiation therapy and CCNU.
Topics: Animals; Dog Diseases; Dogs; Fatal Outcome; Immunohistochemistry; Lomustine; Magnetic Resonance Imag | 2012 |
Cervicothoracic syringohydromyelia associated with a prosencephalic mass in a dog.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2012 |
Long-term chemotherapy with lomustine of intracranial meningioma occurring in a miniature schnauzer.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Brain; Dog Diseases; Dogs; Drug Administra | 2006 |
Lomustine for the treatment of gastrointestinal mast cell tumour in a dog.
Topics: Animals; Antineoplastic Agents, Alkylating; Dog Diseases; Dogs; Gastrointestinal Neoplasms; Lomustin | 2006 |
Acquired cervical syringomyelia secondary to a brainstem meningioma in a maltese dog.
Topics: Animals; Dog Diseases; Dogs; Female; Lomustine; Magnetic Resonance Imaging; Meningeal Neoplasms; Men | 2006 |
Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005).
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Dog Diseases; Dogs; Dos | 2007 |